top of page
Korea is repricing its medicines. It is reshuffling your go-to-market strategy.
Korea has cut generic prices to 45% of the originator price and opened confidential net pricing. For companies entering through a local partner, the reform changes who is worth partnering with, and what the contract needs to say.
AsiaBioBridge
Oct 85 min read


bottom of page
